Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Loeb, Keith R ^a,b   Asgari, Maryam M ^b,e   Hawes, Stephen E ^b   Feng, Qinghua ^b   Stern, Joshua E ^b   Jiang, Mingjun ^d   Argenyi, Zsolt B ^b   de Villiers, Ethel Michele ^c   Kiviat, Nancy B ^b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d National Academy of Medical Sciences   (China)

^e DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; VIRUS DNA;

AGED; ARTICLE; CODON; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATION; MUTATION RATE; PAPILLOMAVIRUS INFECTION; PROTEIN POLYMORPHISM; RISK FACTOR; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; GENETIC POLYMORPHISM; GENETICS; ISOLATION AND PURIFICATION; PAPILLOMA VIRUS; PATHOLOGY; SKIN; SKIN TUMOR; VIROLOGY;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CODON; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; MUTATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, GENETIC; SKIN; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84860189128     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034422     Document Type: Article

References (104)

1. Miller DL, Weinstock MA, (1994) Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 30: 774-778.
2. Preston DS, Stern RS, (1992) Nonmelanoma cancers of the skin. The New England journal of medicine 327: 1649-1662.
3. Rees J, (1994) Genetic alterations in non-melanoma skin cancer. J Invest Dermatol 103: 747-750.
4. Armstrong BK, Kricker A, (1995) Skin cancer. Dermatol Clin 13: 583-594.
5. Rowe DE, Carroll RJ, Day CL Jr, (1992) Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. Journal of the American Academy of Dermatology 26: 976-990.
6. Brash D, Rudolph J, Simon J, Lin A, McKenna G, (1991) A Role for Sunlight in Skin Cancer: UV-Induced p53 Mutations in Squamous Cell Carcinoma. Proceedings of the National Academy of Sciences 88: 10124-10128.
7. Moshinsky DJ, Wogan GN, (1997) UV-induced mutagenesis of human p53 in a vector replicated in Saccharomyces cerevisiae. Proceedings of the National Academy of Sciences of the United States of America 94: 2266-2271.
8. Amstad P, Hussain SP, Cerutti P, (1994) Ultraviolet B light-induced mutagenesis of p53 hotspot codons 248 and 249 in human skin fibroblasts. Molecular carcinogenesis 10: 181-188.
9. Harris CC, (1993) p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 262: 1980-1981.
10. Kubo Y, Urano Y, Yoshimoto K, Iwahana H, Fukuhara K, et al. (1994) p53 gene mutations in human skin cancers and precancerous lesions: comparison with immunohistochemical analysis. J Invest Dermatol 102: 440-444.
11. Ren ZP, Hedrum A, Pontén F, Nistér M, Ahmadian A, et al. (1996) Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplastic keratinocytes. Oncogene 12: 765-773.
12. Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, et al. (1993) Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 90: 4216-4220.
13. McGregor JM, Berkhout RJ, Rozycka M, ter Schegget J, Bouwes Bavinck JN, et al. (1997) p53 mutations implicate sunlight in post-transplant skin cancer irrespective of human papillomavirus status. Oncogene 15: 1737-1740.
14. Jonason AS, Kunala S, Price GJ, Restifo RJ, Spinelli HM, et al. (1996) Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA 93: 14025-14029.
15. Strauss BS, (1997) Silent and multiple mutations in p53 and the question of the hypermutability of tumors. Carcinogenesis 18: 1445-1452.
16. Kiviat NB, (1999) Papillomaviruses in non-melanoma skin cancer: epidemiological aspects. Seminars in cancer biology 9: 397-403.
17. Purdie KJ, Surentheran T, Sterling JC, Bell L, McGregor JM, et al. (2005) Human papillomavirus gene expression in cutaneous squamous cell carcinomas from immunosuppressed and immunocompetent individuals. J Invest Dermatol 125: 98-107.
18. Harwood CA, Surentheran T, McGregor JM, Spink PJ, Leigh IM, et al. (2000) Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 61: 289-297.
19. Forslund O, Antonsson A, Nordin P, Stenquist B, Hansson BG, (1999) A broad range of human papillomavirus types detected with a general PCR method suitable for analysis of cutaneous tumours and normal skin. The Journal of general virology 80 (Pt 9): 2437-2443.
20. Bouwes Bavinck JN, Neale RE, Abeni D, Euvrard S, Green AC, et al. (2010) Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Res 70: 9777-9786.
21. Karagas MR, Nelson HH, Sehr P, Waterboer T, Stukel TA, et al. (2006) Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. Journal of the National Cancer Institute 98: 389-395.
22. Andersson K, Waterboer T, Kirnbauer R, Slupetzky K, Iftner T, et al. (2008) Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 17: 189-195.
23. Patel AS, Karagas MR, Perry AE, Nelson HH, (2008) Exposure profiles and human papillomavirus infection in skin cancer: an analysis of 25 genus beta-types in a population-based study. J Invest Dermatol 128: 2888-2893.
24. Feltkamp MCW, de Koning MNC, Bavinck JNB, ter Schegget J, (2008) Betapapillomaviruses: innocent bystanders or causes of skin cancer. J Clin Virol 43: 353-360.
25. Waterboer T, Abeni D, Sampogna F, Rother A, Masini C, et al. (2008) Serological association of beta and gamma human papillomaviruses with squamous cell carcinoma of the skin. Br J Dermatol 159: 457-459.
26. Andersson K, Waterboer T, Kirnbauer R, Slupetzky K, Iftner T, et al. (2008) Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions. Cancer Epidemiol Biomarkers Prev 17: 189-195.
27. Asgari MM, Kiviat NB, Critchlow CW, Stern JE, Argenyi ZB, et al. (2008) Detection of Human Papillomavirus DNA in Cutaneous Squamous Cell Carcinoma among Immunocompetent Individuals. J Invest Dermatol 128: 1409-1417.
28. Rollison DE, Pawlita M, Giuliano AR, Iannacone MR, Sondak VK, et al. (2008) Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers. Int J Cancer 123: 2337-2342.
29. Forslund O, Iftner T, Andersson K, Lindelof B, Hradil E, et al. (2007) Cutaneous human papillomaviruses found in sun-exposed skin: Beta-papillomavirus species 2 predominates in squamous cell carcinoma. J Infect Dis 196: 876-883.
30. Vasiljevic N, Hazard K, Dillner J, Forslund O, (2008) Four novel human betapapillomaviruses of species 2 preferentially found in actinic keratosis. J Gen Virol 89: 2467-2474.
31. Struijk L, van der Meijden E, Kazem S, ter Schegget J, de Gruijl FR, et al. (2008) Specific betapapillomaviruses associated with squamous cell carcinoma of the skin inhibit UVB-induced apoptosis of primary human keratinocytes. J Gen Virol 89: 2303-2314.
32. Alotaibi L, Provost N, Gagnon S, Franco EL, Coutlee F, (2006) Diversity of cutaneous human papillomavirus types in individuals with and without skin lesion. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 36: 133-140.
33. Sakamuro D, Sabbatini P, White E, Prendergast GC, (1997) The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15: 887-898.
34. Dumont P, Leu JI, Della Pietra AC, 3rd, George DL, Murphy M, (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature genetics 33: 357-365.
35. Walker KK, Levine AJ, (1996) Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proceedings of the National Academy of Sciences of the United States of America 93: 15335-15340.
36. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, et al. (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Molecular and cellular biology 19: 1092-1100.
37. Zhu F, Dollé MET, Berton TR, Kuiper RV, Capps C, et al. (2010) Mouse models for the p53 R72P polymorphism mimic human phenotypes. Cancer Res 70: 5851-5859.
38. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, et al. (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25: 47-54.
39. Schwartz JL, Plotnik D, Slovic J, Li T, Racelis M, et al. (2011) Tp53 codon-72 polymorphisms identify different radiation sensitivities to g2-chromosome breakage in human lymphoblast cells. Environmental and molecular mutagenesis 52: 77-80.
40. Azzam GA, Frank AK, Hollstein M, Murphy ME, (2011) Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model. Cell Cycle 10: 1352-1355.
41. Frank AK, Leu JI, Zhou Y, Devarajan K, Nedelko T, et al. (2011) The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Molecular and cellular biology 31: 1201-1213.
42. Sjalander A, Birgander R, Saha N, Beckman L, Beckman G, (1996) p53 polymorphisms and haplotypes show distinct differences between major ethnic groups. Human heredity 46: 41-48.
43. Yang W, Zhang Y, Tian X, Ning T, Ke Y, (2008) p53 Codon 72 polymorphism and the risk of esophageal squamous cell carcinoma. Mol Carcinog 47: 100-104.
44. Cáceres D, Quiñones L, Schroeder J, Gil L, Irarrázabal C, (2009) Association Between p53 codon 72 Genetic Polymorphism and Tobacco Use and Lung Cancer Risk. Lung 187: 110-115.
45. Lee J-M, Shun C-T, Wu M-T, Chen Y-Y, Yang S-Y, et al. (2006) The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer. Mutat Res 594: 181-188.
46. Pantelis A, Pantelis D, Ruemmele P, Hartmann A, Hofstaedter F, et al. (2007) p53 Codon 72 polymorphism, loss of heterozygosity and high-risk human papillomavirus infection in a low-incidence German esophageal squamous cell carcinoma patient cohort. Oncol Rep 17: 1243-1248.
47. Szymanowska A, Jassem E, Dziadziuszko R, Borg A, Limon J, et al. (2006) Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer 52: 9-14.
48. Koushik A, Tranah GJ, Ma J, Stampfer MJ, Sesso HD, et al. (2006) p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer 119: 1863-1868.
49. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, et al. (1998) Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393: 229-234.
50. Whibley C, Pharoah PDP, Hollstein M, (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9: 95-107.
51. de Oliveira WRP, Rady PL, Grady J, Hughes TK, Neto CF, et al. (2004) Association of p53 arginine polymorphism with skin cancer. Int J Dermatol 43: 489-493.
52. McGregor JM, Harwood CA, Brooks L, Fisher SA, Kelly DA, et al. (2002) Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. J Invest Dermatol 119: 84-90.
53. Brant O, Hoffmann M, Kanappilly A, Görögh T, Gottschlich S, (2007) P53 codon 72 polymorphism in squamous cell carcinoma of the head and neck region. Anticancer Res 27: 3301-3305.
54. Dokianakis DN, Koumantaki E, Billiri K, Spandidos DA, (2000) P53 codon 72 polymorphism as a risk factor in the development of HPV-associated non-melanoma skin cancers in immunocompetent hosts. Int J Mol Med 5: 405-409.
55. O'Connor DP, Kay EW, Leader M, Atkins GJ, Murphy GM, et al. (2001) p53 codon 72 polymorphism and human papillomavirus associated skin cancer. J Clin Pathol 54: 539-542.
56. Bastiaens MT, Struyk L, Tjong-A-Hung SP, Gruis N, ter Huurne J, et al. (2001) Cutaneous squamous cell carcinoma and p53 codon 72 polymorphism: a need for screening? Mol Carcinog 30: 56-61.
57. Bendesky A, Rosales A, Salazar A, Sordo M, Peniche J, et al. (2007) p53 codon 72 polymorphism, DNA damage and repair, and risk of non-melanoma skin cancer. Mutat Res 617: 38-44.
58. Hoffmann M, Scheunemann D, Fazel A, Görögh T, Kahn T, et al. (2009) Human papillomavirus and p53 polymorphism in codon 72 in head and neck squamous cell carcinoma. Oncol Rep 21: 809-814.
59. Han J, Cox DG, Colditz GA, Hunter DJ, (2006) The p53 codon 72 polymorphism, sunburns, and risk of skin cancer in US Caucasian women. Mol Carcinog 45: 694-700.
60. Stefanaki I, Stratigos AJ, Dimisianos G, Nikolaou V, Papadopoulos O, et al. (2007) p53 codon 72 Pro homozygosity increases the risk of cutaneous melanoma in individuals with dark skin complexion and among noncarriers of melanocortin 1 receptor red hair variants. Br J Dermatol 156: 357-362.
61. Li C, Chen K, Liu Z, Wang L-E, Gershenwald JE, et al. (2008) Polymorphisms of TP53 Arg72Pro, but not p73 G4C14&A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. J Invest Dermatol 128: 1585-1588.
62. Nan H, Qureshi AA, Hunter DJ, Han J, (2008) Interaction between p53 codon 72 polymorphism and melanocortin 1 receptor variants on suntan response and cutaneous melanoma risk. Br J Dermatol 159: 314-321.
63. Szybka M, Zakrzewska M, Rieske P, Pasz-Walczak G, Kulczycka-Wojdala D, et al. (2009) cDNA sequencing improves the detection of P53 missense mutations in colorectal cancer. BMC Cancer 9: 278.
64. Alam M, (2001) Cutaneous squamous-cell carcinoma. N Engl J Med 344: 975-983.
65. Garcia-Zuazaga J, Olbricht SM, (2008) Cutaneous squamous cell carcinoma. Advances in dermatology 24: 33-57.
66. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, et al. (1993) Gain of function mutations in p53. Nature genetics 4: 42-46.
67. Brachmann RK, Vidal M, Boeke JD, (1996) Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proceedings of the National Academy of Sciences of the United States of America 93: 4091-4095.
68. Hainaut P, Hollstein M, (2000) p53 and human cancer: the first ten thousand mutations. Advances in cancer research 77: 81-137.
69. Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, et al. (1998) IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic acids research 26: 205-213.
70. Hjortsberg L, Rubio-Nevado JM, Hamroun D, Béroud C, Claustre M, et al. (2008) The p53 Mutation handbook 2.0, available online;http://p53.free.fr.
71. Durinck S, Ho C, Wang NJ, Liao W, Jakkula LR, et al. (2011) Temporal dissection of tumorigenesis in primary cancers. Cancer discovery 1: 137-143.
72. Ren ZP, Ahmadian A, Pontén F, Nistér M, Berg C, et al. (1997) Benign clonal keratinocyte patches with p53 mutations show no genetic link to synchronous squamous cell precancer or cancer in human skin. Am J Pathol 150: 1791-1803.
73. zur Hausen H, (1991) Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184: 9-13.
74. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, et al. (1992) Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstetrics and gynecology 79: 328-337.
75. Arends MJ, Donaldson YK, Duvall E, Wyllie AH, Bird CC, (1993) Human papillomavirus type 18 associates with more advanced cervical neoplasia than human papillomavirus type 16. Human pathology 24: 432-437.
76. Forslund O, (2007) Genetic diversity of cutaneous human papillomaviruses. The Journal of general virology 88: 2662-2669.
77. Arron ST, Ruby JG, Dybbro E, Ganem D, Derisi JL, (2011) Transcriptome Sequencing Demonstrates that Human Papillomavirus Is Not Active in Cutaneous Squamous Cell Carcinoma. J Invest Dermatol.
78. Fallai C, Perrone F, Licitra L, Pilotti S, Locati L, et al. (2009) Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status. Int J Radiat Oncol Biol Phys 75: 1053-1059.
79. Mitra S, Banerjee S, Misra C, Singh RK, Roy A, et al. (2007) Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian patient population. J Clin Pathol 60: 1040-1047.
80. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, et al. (2011) The Mutational Landscape of Head and Neck Squamous Cell Carcinoma. Science 333: 1157-1160.
81. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, et al. (2011) Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1. Science 333: 1154-1157.
82. Fei JW, Wei QX, Angel P, de Villiers EM, (2005) Differential enhancement of a cutaneous HPV promoter by DeltaNP63alpha, Jun and mutant p53. Cell Cycle 4: 689-696.
83. Fei JW, de Villiers EM, (2008) Degradation of HPV20E6 by p53: Delta Np63 alpha and mutant p53R248W protect the wild type p53 mediated caspase-degradation. International journal of cancer Journal international du cancer 123: 108-116.
84. Li X, Coffino P, (1996) High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. Journal of virology 70: 4509-4516.
85. Jackson S, Harwood C, Thomas M, Banks L, Storey A, (2000) Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 14: 3065-3073.
86. Underbrink MP, Howie HL, Bedard KM, Koop JI, Galloway DA, (2008) E6 Proteins from Multiple Human Betapapillomavirus Types Degrade Bak and Protect Keratinocytes from Apoptosis after UVB Irradiation. J Virol 82: 10408-10417.
87. Yutsudo M, Tanigaki T, Kanda R, Sasagawa T, Inoue T, et al. (1994) Involvement of human papillomavirus type 20 in epidermodysplasia verruciformis skin carcinogenesis. Journal of clinical microbiology 32: 1076-1078.
88. Orth G, (1987) Epiderodysplasia verruciformis. In: Salzman NP, Howley PM, editors. The Papovaviridae New York Plenum.
89. de Oliveira WR, Rady PL, Grady J, Hughes TK, Neto CF, et al. (2004) Association of p53 arginine polymorphism with skin cancer. International journal of dermatology 43: 489-493.
90. Cairey-Remonnay S, Humbey O, Mougin C, Algros MP, Mauny F, et al. (2002) TP53 polymorphism of exon 4 at codon 72 in cutaneous squamous cell carcinoma and benign epithelial lesions of renal transplant recipients and immunocompetent individuals: lack of correlation with human papillomavirus status. The Journal of investigative dermatology 118: 1026-1031.
91. Mantovani F, Tocco F, Girardini J, Smith P, Gasco M, et al. (2007) The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nature structural & molecular biology 14: 912-920.
92. Salvioli S, Bonafe M, Barbi C, Storci G, Trapassi C, et al. (2005) p53 codon 72 alleles influence the response to anticancer drugs in cells from aged people by regulating the cell cycle inhibitor p21WAF1. Cell Cycle 4: 1264-1271.
93. Siddique M, Sabapathy K, (2006) Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25: 3489-3500.
94. Piao JM, Kim HN, Song HR, Kweon SS, Choi JS, et al. (2011) p53 codon 72 polymorphism and the risk of lung cancer in a Korean population. Lung Cancer.
95. Li Y, Qiu LX, Shen XK, Lv XJ, Qian XP, et al. (2009) A meta-analysis of TP53 codon 72 polymorphism and lung cancer risk: evidence from 15,857 subjects. Lung Cancer 66: 15-21.
96. Mojtahedi Z, Hashemi SB, Khademi B, Karimi M, Haghshenas MR, et al. (2010) p53 codon 72 polymorphism association with head and neck squamous cell carcinoma. Brazilian journal of otorhinolaryngology 76: 316-320.
97. Xu B, Xu Z, Cheng G, Min ZC, Mi Y, et al. (2010) Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese. Cancer genetics and cytogenetics 202: 76-81.
98. Jha P, Pathak P, Chosdol K, Suri V, Sharma MC, et al. (2011) TP53 polymorphisms in gliomas from Indian patients: Study of codon 72 genotype, rs1642785, rs1800370 and 16 base pair insertion in intron-3. Experimental and molecular pathology 90: 167-172.
99. Leverrier S, Bergamaschi D, Ghali L, Ola A, Warnes G, et al. (2007) Role of HPV E6 proteins in preventing UVB-induced release of pro-apoptotic factors from the mitochondria. Apoptosis: an international journal on programmed cell death 12: 549-560.
100. Hu Y, McDermott MP, Ahrendt SA, (2005) The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 11: 2502-2509.
101. Zawlik I, Kita D, Vaccarella S, Mittelbronn M, Franceschi S, et al. (2008) Common Polymorphisms in the MDM2 and TP53 Genes and the Relationship between TP53 Mutations and Patient Outcomes in Glioblastomas. Brain Pathol 19: 188-194.
102. Galic V, Willner J, Wollan M, Garg R, Garcia R, et al. (2007) Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer 46: 239-247.
103. Li F, Sturgis EM, Chen X, Zafereo ME, Wei Q, et al. (2010) Association of p53 codon 72 polymorphism with risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer 116: 2350-2359.
104. Guan B, Wang TL, Shih Ie M, (2011) ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer research 71: 6718-6727.